Hansa Biopharma announces positive reimbursement decision fo

/PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that it...

Related Keywords

Sweden , Czech Republic , Prague , Praha , Hlavníesto , Stockholm , Jordan , Czech , Ondrej Viklicky , Hansa Biopharma , Prnewswire Hansa Biopharma , Klaus Sindahl , Head Transplant Center , Institute For Clinical , European Union , Czech State Institute Of Drug , European Medicines Agency , Czech Coordination Centre For Transplantation , European Medicines Agency Ema Priority , Professor Ondrej Viklicky , Experimental Medicine , Human Leukocyte Antigens , European Marketing Authorization , End Stage Renal Disease , Product Characteristics , Nasdaq Stockholm , Czech State Institute , Drug Control , Czech Coordination Centre , Eurostam Report , Dial Transplant , Englj Med , European Medicines , Newsletter Transplant , Hansa Biopharma Ab ,